ESMO25: On radiopharmaceutical possibilities in oncology, with Dr Ebrahim Delpassand

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix, an emerging, clinical-stage biotech company advancing a best-in-class pipeline of radiopharmaceuticals for PET imaging and radionuclide therapy.

Dr Delpassand discusses the company’s new data, having already developed several innovative radiopharmaceutical products, including the FDA approved 64Cu-Dotatate, a diagnostic radiopharmaceutical for neuroendocrine cancer, which is now licensed to Curium Pharma for manufacturing and distribution.

Additionally, the conversation explores the way in which radiopharmaceuticals provide solutions where other cell and precisions therapies fall short, as well as this year’s Congress as a whole.

Watch this and other conversations from ESMO 2025 here.